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Background: Although new individual treatments continue to reshape the landscape of clinical care in patients
with lung cancer, most of the progress has been mainly of benefit to patients with lung adenocarcinomas rather
than squamous cell lung carcinoma (SQCLC). Our study aimed to determine whether the epidermal growth factor
receptor (EGFR) gene mutation is present in pure SQCLC. We further determined the mutation frequency and the
clinical and pathological features of groups that are in high risk for EGFR mutation.
Methods: A total of 185 Chinese patient specimens diagnosed as SQCLC in the Shanghai Chest Hospital at the
Shanghai Jiao Tong University were selected for this study. Hematoxylin-eosin stained slides for all cases were
reviewed and evaluated by immunohistochemical analysis with the aim of selecting samples with pure SQCLC. After
screening, 22 cases were eliminated and 163 pure SQCLC cases remained. Amplification Refractory Mutation System
was used to detect the EGFR gene mutation status in the 163 SQCLC specimens.
Results: A total of 28 cases with EGFR mutation were detected among the 163 specimens. The EGFR mutation rate
was 17.2% (28/163). Sex and smoking status were significantly associated with the status of EGFR gene mutation
(P = 0.022 and P = 0.049, respectively). Age and degree of differentiation were not significantly correlated to EGFR
mutation (P = 0.730 and P = 0.651, respectively).
Conclusions: EGFR mutations are present in pure SQCLC, which are more frequently detected in females and
nonsmoker patients. Our results indicate the importance for all patients with SQCLC to have EGFR mutation status
examined. These patients with activating EGFR mutation could accept tyrosine kinase inhibitors (TKIs) treatment.
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Our understanding of the molecular mechanisms that
underlie the development of non-small cell lung carcin-
oma (NSCLC) has increased significantly during the last
decade. Although new discoveries continue to reshape
the landscape of clinical care, most of the progress has
been mainly of benefit to patients with adenocarcinomas
of the lung [1]. The 45th American Society of Clinical
Oncology (ASCO2009) stated that epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
should be the treatment of choice for advanced NSCLC* Correspondence: jiezhang49@hotmail.com
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unless otherwise stated.patients with EGFR mutations. A recent study showed
that squamous cell lung cancer (SQCLC) accounts for
20–30% of NSCLC [2]. Among the major histological
subtypes of NSCLC, the study of the molecular abnor-
malities in SQCLC has recently started to make minor
progress [3]. However, there is still a lack of effective tar-
geted therapy for SQCLC.
The current consensus in the medical community is
that EGFR mutations are predominantly found in lung
adenocarcinoma patients who are Asian, female, and
non- or mild smokers [4]. The National Comprehensive
Cancer Network (NCCN) 2012 guidelines for NSCLC
treatment stated that EGFR mutation analysis and ALK
gene rearrangement detection should not be routinelyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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et al. conducted a retrospective study, in which 92 pa-
tients with advanced SQCLC and unknown EGFR muta-
tion status were treated with erlotinib. The results
showed an overall response rate (ORR) of 17.4% and a
disease control rate (DCR) of 27.2%. Progression-free
survival (PFS) and overall survival (OS) were both longer
in patients with disease control than in those with pro-
gressive disease (7.8 vs. 1.3 months and 20.7 vs.
2.7 months, respectively; P < 0.0001 for both). From the
results of the study, researchers concluded that a signifi-
cant proportion of SQCLC patients could benefit from
erlotinib treatment, and thus evaluation of EGFR muta-
tion status would be necessary [6]. However, the EGFR
mutation rate in resected SQCLC specimens is 0–7.4%
[7,8] and 1–15% in biopsied SQCLC specimens [9].
These rates are much lower than the 42.7% (33.5–56.8%)
rate found in lung adenocarcinomas [10]. Adenocarcin-
oma compositions could alter the EGFR mutation sta-
tus of SQCLC, so whether the relevant mutation in
SQCLC samples is caused by the inclusion of adenocar-
cinoma compositions is controversial. Thus far, few
studies have shown EGFR mutation in SQCLC, and
patients with activating EGFR mutation responded to
TKIs treatment [11].
Thus, the primary objective of this study was to
enhance the diagnostic accuracy for SQCLC using
hematoxylin-eosin (H&E) and immunohistochemical
(IHC) analyses. The non-SQCLC component was ex-
cluded to determine the presence of EGFR gene muta-
tion in pure SQCLC. The pathological and clinical
features of patients with the EGFR gene mutation status
are also summarized. The secondary objective of this
study was to examine the response of patients, with pure
SQCLC and an EGFR mutation, to TKIs treatment.
Methods
Study samples
Tumor specimens were obtained from 185 Chinese
patients with SQCLC that were surgically resected in the
Shanghai Chest Hospital at Shanghai Jiao Tong Univer-
sity (Shanghai, China) between June 2006 and June
2012. A total of 119 males and 66 females, with a me-
dian age of 62.4 years, were included in the study. The
research has been approved by the Ethic Committee,
Shanghai Chest Hospital, Shanghai Jiao Tong University,
and the approval is added as in Additional file 1. All pa-
tients provided written informed consent, and one of pa-
tient’s informed consent is added as in Additional file 2.
Study methods
Sample selection
H&E stained specimen slides were read by two experi-
enced pulmonary pathologists and the diagnoses weremade according to the 2004 WHO classification system
for lung carcinoma. Each pathologist classified the
tumor specimens independently and unanimous agree-
ment was obtained. Samples were obtained from four
different regions of each tumor. To exclude mixed, non-
SQCLC tumor compositions, the highest differentiated
sections in the tumors were selected for IHC analysis
and DNA extraction. The differentiation of SQCLC was
categorized as follows: well differentiated, more than
50% of obvious keratin pearl or intercellular bridge
observed in tumor tissues; moderately differentiated,
20–50% of keratin pearl or intercellular bridge observed
in tumor tissues; and poorly differentiated, less than 20%
of keratin pearl or intercellular bridge.
IHC analysis
TTF-1 (Clone 8G7G3/1, DakoCytomation, Glostrup,
Denmark), CK7 (Clone OV-TL 12/30, DakoCytomation),
ΔNP63 (P40, Calbiochem, California, USA) and high
molecular cytokeratin (Clone 34βE12, DakoCytomation)
were used for examination of the pathological histology
that had been identified through H&E staining to ex-
clude mixed and inconspicuous, adenocarcinoma com-
ponents. Tissue sections were deparaffinized using
xylene and dehydrated in alcohol. Antigen-retrieval was
performed by heating the slides in 0.1 M sodium citrate
(pH 6.0) for 10 min. Tissue slides were incubated in
0.3% H2O2 for 10 min to block endogenous peroxidase
activity. Sections were incubated with primary antibody
for 30 min at room temperature. Sections incubated with
antibody diluents (Immunologic, Duiven, Netherlands)
were used as the negative control. Sections were devel-
oped using the Dako EnVision™ visualization system
(DakoCytomation). Pretreatment conditions and antibody
dilutions are available upon request.
DNA extraction and mutation test
The pure squamous cell cancers were determined by
IHC analysis results. ΔNP63 and 34βE12 were positive,
and TTF-1 and CK7 were negative. The area of residual,
alveolar epithelium was avoided when acquiring the
sample tissues (Figure 1) to ensure that the EGFR gene
mutation was present in pure SQCLC. DNA was
extracted from five serial slices of a 5-μm paraffin sec-
tion using the DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany) following the manufacturer’s protocol. The
highly sensitive method Amplification Refractory
Mutation System (ARMS) (ADx-EG01, Xiamen, China)
was used to detect the EGFR gene mutation status [12,13].
Statistical methods
Univariate analysis was conducted on sex, age, smoking
status and the degree of differentiation using Fisher’s exact
test to evaluate the effects of clinical and pathological
Figure 1 Method for obtaining pure SQCLC tissues for detection of EGFR gene mutation. [A] HE stained slice diagnosed as SQCLC.
[B] TTF-1 staining of the residual alveolar epithelium. When obtaining the SQCLC tissues for mutation analysis, the positive regions (indicated
by green borders) were avoided. [C] ΔNP63 staining. The region outlined by the green border was used to detect the EGFR gene mutation status.
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All statistical tests were done using SPSS17.0 software
(http://www.spss.com, IBM Corp., Chicago, IL). Two-
tailed t-tests were used and P values < 0.05 were consid-
ered significant.
Results
H&E staining and IHC analysis
A total of 185 surgical SQCLC samples were examined.
Ten samples were excluded after H&E staining owing to
the SQCLC sample containing less than a 10% portion
of mixed adenocarcinoma, or lymphoepithelioma-like
carcinoma, or basal-like large cell carcinoma that had
been diagnosed as SQCLC. An additional 12 samples
were excluded owing to IHC results. In some cases, all
results were negative after analysis using the primary
antibodies ΔNP63 (P40), TTF-1, CK7 and 34βE12, and
the cases should be diagnosed as large cell carcinoma. In
other cases, the results of ΔNP63 (P40) and 34βE12 were
negative but positive for TTF-1 and CK7, and the cases
should be diagnosed as poorly differentiated adenocar-
cinoma (Figure 2). The remaining 163 cases were en-
rolled in the study to evaluate the EGFR gene mutation
status in pure SQCLC.
A total of 114 (69.9%) males and 49 (30.1%) females
with a median age of 61.3 years (range 33–81 years)
were enrolled. Cases were divided into three groupsFigure 2 A poorly differentiated adenocarcinoma with squamous mo
diagnosed as poorly differentiated SQCLC without IHC analysis. [B] Positivebased on age, and included 11 cases 30–49 years of age,
123 cases 50–69 years of age and 29 cases ≥70 years of
age. In total, 59 cases were considered as well differenti-
ated, 56 moderately differentiated and 48 poorly differ-
entiated. A total of 78 patients were non-smokers, 61
patients were smokers and in 24 cases, smoking status
was unknown.
EGFR gene mutation analysis
An EGFR gene mutation was detected in 28 of the
163 samples, giving a mutation rate of 17.2% (Table 1).
There were 16 cases with 19del mutation and 11
cases with 21L858R mutation, and one 64 years old
female smoking patient with poorly differentiation
SQCLC harbored both 19del and 21L858R mutations.
Sex and smoking status were significantly associated
with the rate of EGFR gene mutation (P = 0.022 and
P = 0.049, respectively). Age and degree of differenti-
ation were not significantly correlated to EGFR gene
mutation (P = 0.730 and P = 0.651, respectively).
Discussion
EGFR-TKIs have been proven to be effective for treating
NSCLC cases with EGFR mutations. Therefore, many
studies have focused on patients with the presence of
active EGFR mutations, especially those with adenocar-
cinoma histology. Thus far, studies involving EGFR generphology. [A] The HE stained specimen from this case could be
TTF-1 stained specimen from the same case.
Table 1 Baseline demographic, clinical characteristics and the corresponding EGFR gene mutation ratio




Male 14 12 2 100 114 12.3%
Female 14 5 10 35 49 28.6%
Degree of differentiation 0.651
Well 10 6 4 49 59 16.7%
Moderately 8 2 6 48 56 14.3%
Poorly 10 9 2 38 48 20.8%
Age 0.730
30-49 years 2 2 0 9 11 26.2%
50-69 years 23 13 11 100 123 11.5%
≥70 years 3 2 1 26 29 12.5%
Smoking status 0.049
Non-smoking 16 10 6 45 61 26.2%
Smoking 9 5 5 69 78 11.5%
Unknown 3 2 1 21 24 12.5%
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SQCLC patients with these mutations have been very
few [11] and there has been little consensus in the re-
sults. In 2014, Kim et al. reported that an EGFR muta-
tion rate of 6% in SQCLC patients [3]. In 2011,
researchers from the Netherlands carried out a multi-
center study and found no EGFR gene mutation in
SQCLC patients [7]. In 2010, Japanese researchers
found that the rate of EGFR gene mutation in resected
SQCLC specimens was 7.4% [8]. In 2007, researchers
in Korea found a response to TKI treatment in 69 pa-
tients with advanced SQCLC and an EGFR mutation
rate up to 15% (3/20) [9]. In addition, their results
indicated that EGFR gene mutation could be the pre-
dictive factor for the response to TKIs, although the
efficacy was lower for SQCLC than for adenocarcin-
oma. In the current study, IHC analysis was used to
select only pure SQCLC to help elucidate whether the
EGFR gene is mutated in SQCLC and, if so, to deter-
mine the mutation rate, as well as the clinical and
pathological features in high risk groups. In 2010,
William Travis pointed out that there are some limi-
tations on samples obtained via bronchoscopy or
transthoracic needle biopsy when making diagnoses
based on pathology and when detecting genomic
alterations, owing to the high degree of heterogeneity
in lung cancers [14]. Thus, only surgical SQCLC
specimens were included in the current study. In
addition, primary antibody P40 was used instead of
P63, due to its higher specificity when confirming
squamous cell cancers [15,16].In our study, we found a total rate of 17.2% for the
EGFR gene mutation in patients with SQCLC. This rate
was higher than that found in our previous analyses
(0–15%) [3,7-9]. There could be several possible expla-
nations for the different results. One possibility could
reflect the different sensitivities among the different
methods used for analyses. Most of the former studies
detected the EGFR gene mutation by direct DNA se-
quencing, which has a sensitivity of only 70%, much
lower than the 99% sensitivity of ARMS [12,13]. Thus,
the different detection assay could interfere with the
mutation relevance rate. A second explanation may be
owing to the difference in the sex ratio of the enrolled
patients. Because the incidence of SQCLC is lower in
females, as also evident in the current study, fewer fe-
males were included. The current study showed that
the rate of EGFR gene mutation in females with
SQCLC was 28.6%, which is significantly higher than in
males (12.3%) (P = 0.022). As a result, we speculate that
the total rate of mutation in SQCLC might increase as
the number of female cases increases. A third explan-
ation may involve differences among races and regions,
as the factors that drive genomic alteration between
races are consequential [17,18]. For example, the K-ras
gene mutation is higher in Caucasian NSCLC patients
than in Asian NSCLC patients. Similarly, Asian patients
with adenocarcinoma also have a higher incidence of
the EGFR gene mutation than Caucasian patients. Fur-
thermore, all of our samples are Chinese patients,
which may lead to a different result from other Asian
or Caucasian patients.
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factors in the EGFR gene mutation rate in SQCLC (female:
28.6% and male: 12.3%, P = 0.022; non-smoking:
26.2%, moking: 11.5% and unknown smoking status:
20.8%, P = 0.049). However, age and the degree of differenti-
ation had no affect on the mutation rate. To our know-
ledge, a similar conclusion has not been reported thus far.
If further research finds it to be similar to the EGFR gene
mutation found in adenocarcinoma among high-risk
groups, oncologists should consider testing female and
non/mild smoking SQCLC patients for EGFR gene muta-
tion status and begin TKIs treatment if appropriate.
In 2011, Shukuya et al. [19] carried out a pooled ana-
lysis of published reports regarding the efficacy of gefi-
tinib for use in non-adenocarcinoma, non-small cell
lung cancer patients harboring EGFR mutations. The
analysis showed that gefitinib is less effective in non-
adenocarcinoma NSCLC harboring EGFR mutations
than in adenocarcinoma harboring EGFR mutations
(response rate (RR): 27% vs. 66%, P = 0.000028; DCR:
67–70% vs. 92–93%, P = 0.000014; median progression-
free survival (mPFS): 3.0 vs. 9.4 months, P = 0.0001). We
could not obtain adequate data regarding the response
to TKIs treatment due to the limited number of EGFR
gene mutant SQCLC patients taking TKIs. Follow-up
was done on 13 of the 28 EGFR gene mutant cases in
our study. Of these, four subjects had died and four sub-
jects were in advanced stages of disease and accepted
TKIs treatment. All four acquired clinical benefits from
this treatment. Other driving genomic alterations, such
as in ALK and c-MET genes, have also been gaining
recent attention. However, their mutation rates are lower
(ALK: 1.5–6.7% [20-22], and c-MET: 2–4.1% [23,24]).
Thus, it is of utmost importance that SQCLC patients
have EGFR gene mutation examined and accept the
TKIs treatment if appropriate.
Conclusion
EGFR mutations are present in pure SQCLC, and are
more frequently detected in females and nonsmoker pa-
tients. It is important for all patients with SQCLC to have
EGFR mutation status examined. These patients with acti-
vating EGFR mutation could accept TKIs treatment.
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